Source Ceritinib Powder for Pharmaceutical Research and Development

Strategic Sourcing Guide for Ceritinib Powder Procurement

The global pharmaceutical supply chain relies heavily on the availability of high-purity active pharmaceutical ingredients (APIs) to ensure the continuity of drug manufacturing. Among these critical compounds, Ceritinib powder has emerged as a significant component in oncology treatments. For procurement professionals, sourcing this material requires a disciplined approach that balances technical verification, regulatory compliance, and supply chain resilience. This guide outlines the essential factors buyers must evaluate when procuring Ceritinib powder, focusing on the specific attributes observed in current market listings while adhering to strict evidence-based sourcing principles.

Technical Specifications and Chemical Identity

The foundation of any successful procurement strategy for Ceritinib powder lies in the precise verification of its chemical identity and physical properties. Based on available product data, the core material is identified by the CAS number 1032900-25-6. This unique identifier is the primary method for distinguishing Ceritinib from structurally similar kinase inhibitors, such as Crizotinib (CAS 877399-52-5) or Lenvatinib Mesylate (CAS 857890-39-2), which may appear in the same supplier catalogs.

Buyers must verify the molecular formula, listed as C28h36cln5o3s, and the molecular weight of 558.13514 g/mol. These parameters are non-negotiable for regulatory filings and batch consistency. Physically, the material is described as a white to off-white to pale yellow crystalline powder. The appearance is a critical visual indicator; significant deviations from this color profile may suggest degradation or the presence of impurities. The predicted density is recorded at 1.251±0.06 g/cm3, and the predicted LogP value is 7.26640, indicating high lipophilicity, which influences formulation strategies. The predicted pKa of 10.16±0.10 is also a vital parameter for solubility studies during the drug development phase.

When evaluating suppliers, it is essential to confirm that the product model aligns with the specific grade required. The observed product model designation is HNR-Ceritinib, which serves as a reference point for internal inventory management. However, buyers should not assume that all listings with this model number meet the same purity standards without independent verification. The standard purity threshold observed in the market is greater than 99%, a benchmark that must be validated against the Certificate of Analysis (COA) for every batch received.

Compliance and Certification Frameworks

In the pharmaceutical sector, certification is not merely a formality but a prerequisite for market entry. The supply chain for Ceritinib powder must demonstrate adherence to rigorous quality management systems. The observed product attributes indicate that compliant suppliers typically hold certifications including BP (British Pharmacopoeia), USP (United States Pharmacopeia), ISO HSE, and GMP (Good Manufacturing Practice). These certifications ensure that the manufacturing process meets international standards for safety, efficacy, and quality control.

Buyers must verify the validity of these certifications before placing orders. It is important to note that while these certifications are listed as high-confidence facts for the category, they are not automatically guaranteed for every single transaction or supplier listing. The procurement process requires direct confirmation that the specific batch of Ceritinib powder being sourced is manufactured under a GMP-certified facility. Furthermore, the material is designated as Pharmaceutical Grade, which distinguishes it from industrial or research-grade chemicals that may lack the necessary purity and safety testing.

The storage and handling requirements are also part of the compliance framework. While specific storage temperatures for Ceritinib are not explicitly detailed in the provided data for this specific compound (unlike Lenvatinib Mesylate, which lists Room Temperature), the general pharmaceutical standard implies controlled environments to maintain stability. The observed shelf life is 2 Years, a critical metric for inventory planning and expiration date management. Buyers should ensure that the COA includes stability data supporting this shelf life claim under recommended storage conditions.

Cost Drivers and Pricing Dynamics

Understanding the cost structure of Ceritinib powder is essential for budgeting and negotiation. The observed listed price range in the market spans from 0.2 to 600 USD. This wide variance is not indicative of a single product but rather reflects differences in packaging sizes, purity levels, order volumes, and supplier positioning. The minimum order quantity (MOQ) ranges from 1 to 100 units, suggesting flexibility for both small-scale research projects and large-scale industrial production.

Several factors drive the final cost. First, the packaging configuration plays a significant role; the product packing is listed as "Negotiable," meaning costs will vary based on whether the buyer requires bulk drums, intermediate containers, or specialized sterile packaging. Second, the level of customization available influences pricing. The market data confirms that customization is available, allowing buyers to request specific particle sizes, packaging formats, or labeling requirements, which typically incurs additional charges.

Buyers should be cautious of prices that seem anomalously low. While the lower end of the range is 0.2 USD, this likely corresponds to very small sample sizes or specific promotional offers rather than bulk commercial pricing. Conversely, prices at the higher end may reflect premium packaging, expedited shipping, or bundled quality assurance services. The cost per unit should always be calculated based on the actual quantity ordered and the specific terms of the agreement, rather than the listed price range alone.

Typical Applications and Suitability

Ceritinib powder is primarily intended for pharmaceutical applications, specifically in the development of cancer therapies. The target demographic for products containing this ingredient includes adults, children, and the elderly, indicating a broad potential application scope in clinical settings. However, the procurement of the raw material is distinct from the final product formulation. The buyer's responsibility is to ensure the API meets the specifications required for the intended therapeutic use.

The versatility of the material is supported by its chemical stability and high purity. The "Suitable for" attribute confirms its applicability across different patient populations, but this does not imply that the raw powder itself is administered directly. Instead, it must be processed into a final dosage form, such as tablets or capsules, by a formulation scientist. The high purity (>99%) and the specific test method (HPLC) ensure that the material is suitable for complex pharmaceutical formulations where impurity profiles must be tightly controlled.

It is crucial to distinguish between the raw material and the final drug product. While the powder is suitable for various age groups, the specific dosage and formulation must be determined by clinical data and regulatory approval. Procurement professionals should focus on the quality of the input material, ensuring it supports the rigorous demands of pharmaceutical manufacturing rather than making assumptions about the final therapeutic outcome.

Supplier Evaluation and Quality Control

Selecting the right supplier is perhaps the most critical step in the procurement process. The market data indicates that the origin of the product is often listed as Xian or Shaanxi Xi'an. While this provides a geographical context, it does not guarantee quality. Buyers must evaluate suppliers based on their ability to provide comprehensive documentation, including the Certificate of Analysis (COA). The specific test method for purity verification is HPLC (High-Performance Liquid Chromatography), a gold standard in pharmaceutical analysis.

When evaluating a potential supplier, buyers should request a recent COA that matches the batch number of the product being purchased. The COA must confirm the assay results, ensuring the purity meets the >99% standard. Additionally, the supplier should be able to provide traceability data linking the batch to the manufacturing facility and the raw material sources. The presence of certifications like GMP and ISO HSE should be verified through independent databases or direct communication with the certifying bodies.

Quality control should not end at the point of purchase. Buyers must establish a protocol for incoming quality inspection. This includes visual inspection for the white to off-white to pale yellow crystalline powder appearance and verification of the physical properties against the predicted values. The shelf life of 2 years must be clearly marked on the packaging, and the storage conditions must be maintained throughout the logistics chain to prevent degradation.

Long-Term Procurement Considerations

Sourcing Ceritinib powder is not a one-time transaction but a long-term commitment that requires strategic planning. The availability of customization options allows buyers to adapt to changing market needs, but it also necessitates clear communication of specifications to the supplier. The "Customized" attribute suggests that suppliers can tailor the product, but this requires a defined scope of work and agreed-upon quality parameters.

Supply chain resilience is another key consideration. The observed MOQ of 1 to 100 units offers flexibility, but buyers should aim to establish a consistent ordering schedule to secure priority status with suppliers. Lead times, while not explicitly provided in the data, are a critical factor in production planning. Buyers should negotiate clear delivery timelines and backup plans in case of supply disruptions.

Furthermore, the regulatory landscape for pharmaceuticals is dynamic. Buyers must stay informed about changes in pharmacopoeia standards (BP, USP) and ensure that their suppliers remain compliant. The 2-year shelf life provides a window for inventory management, but buyers should implement a first-expiry-first-out (FEFO) strategy to minimize waste. Finally, the negotiation of packaging terms should be revisited periodically to optimize costs and reduce environmental impact, as the "Negotiable" nature of packing allows for continuous improvement in logistics efficiency.

Comparative Analysis of Key Pharmaceutical Powders

To aid in decision-making, it is helpful to compare Ceritinib with other similar compounds often found in the same supplier catalogs. The following table highlights the distinct chemical and physical properties of Ceritinib relative to Crizotinib and Lenvatinib Mesylate, based on the provided product data.

This comparison underscores the importance of precise identification. While all three compounds are crystalline powders used in pharmaceutical applications, their chemical structures and physical properties differ significantly. Confusing these materials could lead to formulation failures or regulatory non-compliance. Buyers must rigorously cross-reference the CAS number and molecular weight to ensure they are procuring the correct substance.

In conclusion, sourcing Ceritinib powder requires a meticulous approach that prioritizes technical accuracy, regulatory compliance, and supplier reliability. By focusing on the specific attributes of the material, verifying certifications, and understanding the cost drivers, procurement professionals can secure a high-quality supply chain that supports the critical needs of the pharmaceutical industry. The data provided offers a solid foundation for these decisions, but continuous verification and adaptation to market changes remain essential for long-term success.